Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Bipolar disorder
FollowWhat is new in Bipolar disorder research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- AzetukalnerPhase 3 · NCT07217860 · NCT07172516
- BrexpiprazolePhase 3 · NCT04569448
- BupropionPhase 3 · NCT05973786 · NCT05603104
- CannabidiolPhase 3 · NCT05867849 · NCT05457465
- CariprazinePhase 3 · NCT04777357
- ClozapinePhase 3 · NCT05603104
- D-serine solutionPhase 3 · NCT07263022
- EscitalopramPhase 3 · NCT05973786 · NCT05603104
- Esketamine hydrochloridePhase 3 · NCT05603104
- Esketamine Nasal ProductPhase 3 · NCT05603104
- KarXTPhase 3 · NCT06951698 · NCT06951711 · NCT06929273
- KetaminePhase 3 · NCT03573349 · NCT05625555 · NCT05786066
- Ketamine HydrochloridePhase 3 · NCT07569198 · NCT05603104
- LacosamidePhase 3 · NCT07412132
- LamotriginePhase 3 · NCT06929273
- LithiumPhase 3 · NCT05973786 · NCT05603104 · NCT06929273
- LumateperonePhase 3 · NCT06372964 · NCT06229210
- MagPro X100/R30 stimulator, Cool-B70 coilPhase 3 · NCT06986460
- MidazolamPhase 3 · NCT05625555
- ModafinilPhase 3 · NCT07263022
- OlanzapinePhase 3 · NCT05303064
- OLZ/SAMPhase 3 · NCT05303064 · NCT04987229
- PramipexolePhase 3 · NCT07664852
- QuetiapinePhase 3 · NCT05973786 · NCT05603104
- Second-line AntidepressantsPhase 3 · NCT05603104
- Second-line AntipsychoticsPhase 3 · NCT05603104
- SertralinePhase 3 · NCT05973786 · NCT05603104
- ValproatePhase 3 · NCT06929273
- Valproate acidPhase 3 · NCT05973786 · NCT05603104
- VenlafaxinePhase 3 · NCT05973786 · NCT05603104
- Xanomeline/Trospium ChloridePhase 3 · NCT07140913
- RUL LAP-ST (Low-Amplitude Pulse Seizure Therapy - Right Unilateral)Phase 2/3 · NCT06529029
- Sigma-StimPhase 2/3 · NCT06529029
- ABBV-932Phase 2 · NCT07071532 · NCT07220460
- ABX-002Phase 2 · NCT06869187
- ALTO-100Phase 2 · NCT06656416
- BrenipatidePhase 2 · NCT07286175
- IcalcaprantPhase 2 · NCT06696755
- Inert CompoundPhase 2 · NCT03349528
- LB-102Phase 2 · NCT07494305
- Magnesium vitamin B6Phase 2 · NCT05837104
- MelatoninPhase 2 · NCT06226025 · NCT07472075
- Midazolam HydrochloridePhase 2 · NCT07569198
- N-acetyl cysteinePhase 2 · NCT07913542
- NBI-1117568Phase 2 · NCT07288320
- NMDAEPhase 2 · NCT05977023
- OSU6162Phase 2 · NCT05296356
- Perampanel 6 MGPhase 2 · NCT05786066
- Probiotic SupplementPhase 2 · NCT03349528
- PsilocybinPhase 2 · NCT06506019 · NCT06706232
- psilocybin (25 mg)Phase 2 · NCT06943573
- psilocybin 1mg micro-dosePhase 2 · NCT06943573
- Psilocybin therapyPhase 2 · NCT05065294
- Quetiapine (drug)Phase 2 · NCT07654348
- AL001Phase 1/2 · NCT07540338
- Cariprazine DepotPhase 1/2 · NCT07185815
- Cariprazine Depot MTDPhase 1/2 · NCT07185815
- Ibuprofen 800 mgPhase 1/2 · NCT06088732
- Lithium carbonatePhase 1/2 · NCT07540338
- Oral Cariprazine 3 mg/dayPhase 1/2 · NCT07185815
- Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)Phase 1 · NCT03522545
- BXCL501 120 MicrogramsPhase 1 · NCT05025605
- BXCL501 60 MicrogramsPhase 1 · NCT05025605
- BXCL501 80 MicrogramsPhase 1 · NCT05025605
- Functional MRIPhase 1 · NCT06506019
- ItraconazolePhase 1 · NCT07071532
- BrainSonix Pulsar 1002Early phase 1 · NCT06482762
Closest to patients
- Predictors of Intravenous Ketamine Response in TRDPredictors of Intravenous Ketamine Response in TRDMood Disorders Program · Halifax, CanadaPhase 3Results expected 2026
- Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderStudy to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderAlkermes Investigator Site · Colorado Springs, United States + 42 more hospitalsPhase 3Results expected 2026
- Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive TherapyLow Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive TherapyPine Rest Christian Mental Health Services · Grand Rapids, United StatesPhase 2/3Results expected 2026
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Limbic network hyperconnectivity, fasting appetite hormone dysregulation and impaired go/no-go performance in youths with bipolar disorder.
Limbic network hyperconnectivity, fasting appetite hormone dysregulation and impaired go/no-go performance in youths with bipolar disorder.
BJPsych open
PubMed · PMID 42972670Publication
Impact of Cannabis Use on Time to Psychiatric Rehospitalization in Young Adults With Bipolar and Psychotic Disorders: A Survival Analysis.
Impact of Cannabis Use on Time to Psychiatric Rehospitalization in Young Adults With Bipolar and Psychotic Disorders: A Survival Analysis.
The Journal of clinical psychiatry
PubMed · PMID 42814580Publication
Plasma endocannabinoid levels in bipolar disorder: Differences between manic and euthymic states and the impact of cannabis use.
Plasma endocannabinoid levels in bipolar disorder: Differences between manic and euthymic states and the impact of cannabis use.
Journal of affective disorders
PubMed · PMID 42735776Publication
Examination of the intersection of bipolar I disorder status and cannabis use disorder severity in relation to health-related quality-of-life and lifetime suicide attempts.
Examination of the intersection of bipolar I disorder status and cannabis use disorder severity in relation to health-related quality-of-life and lifetime suicide attempts.
Journal of psychiatric research
PubMed · PMID 42664567Trial result
MELODY trial: study protocol for a 12-week randomised controlled trial of adjunctive melatonin, digital cognitive behavioural therapy for insomnia or pill placebo to improve depressive symptoms in young adults with mood disorders.
MELODY trial: study protocol for a 12-week randomised controlled trial of adjunctive melatonin, digital cognitive behavioural therapy for insomnia or pill placebo to improve depressive symptoms in young adults with mood disorders.
BMJ open
PubMed · PMID 42637255
Find fellow researchers
Groups with active Bipolar disorder work.
King's College London
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
University of Toronto
Toronto, Canada
Team details appear once the team leader joins.
Is this your team? Claim it
Centro de Investigación Biomédica en Red de Salud Mental
Madrid, Spain
Team details appear once the team leader joins.
Is this your team? Claim it
Karolinska Institutet
Stockholm, Sweden
Team details appear once the team leader joins.
Is this your team? Claim it
Universitat de Barcelona
Barcelona, Spain
Team details appear once the team leader joins.
Is this your team? Claim it
Inserm
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
University of Copenhagen
Copenhagen, Denmark
Team details appear once the team leader joins.
Is this your team? Claim it
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
Barcelona, Spain
Team details appear once the team leader joins.
Is this your team? Claim it
Mayo Clinic
Rochester, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Instituto de Salud Carlos III
Madrid, Spain
Team details appear once the team leader joins.
Is this your team? Claim it
The University of Melbourne
Melbourne, Australia
Team details appear once the team leader joins.
Is this your team? Claim it